Alnylam Pharmaceuticals (ALNY) Change in Acquisitions & Divestments (2009 - 2026)

Alnylam Pharmaceuticals has reported Change in Acquisitions & Divestments for 18 years, with the latest figure at $213.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 336.64% year-over-year to $213.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 billion (up 24.43% YoY), and the FY2025 full-year result was $1.8 billion, up 14.67% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $213.2 million, down from $1.7 billion in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $1.7 billion in Q4 2025, with the low at -$797.1 million in Q3 2025.
• Historically, Change in Acquisitions & Divestments has averaged $460.8 million across 5 years, with a median of $293.3 million in 2023.
• The largest YoY upside for Change in Acquisitions & Divestments was 3872.55% in 2023 against a maximum downside of 2224.42% in 2023.
• Alnylam Pharmaceuticals' Change in Acquisitions & Divestments stood at $604.7 million in 2022, then jumped by 147.28% to $1.5 billion in 2023, then rose by 1.23% to $1.5 billion in 2024, then gained by 15.11% to $1.7 billion in 2025, then sank by 87.77% to $213.2 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $213.2 million (Q1 2026), $1.7 billion (Q4 2025), and -$797.1 million (Q3 2025), per Business Quant data.